ATE462716T1 - Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen - Google Patents

Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen

Info

Publication number
ATE462716T1
ATE462716T1 AT04796067T AT04796067T ATE462716T1 AT E462716 T1 ATE462716 T1 AT E462716T1 AT 04796067 T AT04796067 T AT 04796067T AT 04796067 T AT04796067 T AT 04796067T AT E462716 T1 ATE462716 T1 AT E462716T1
Authority
AT
Austria
Prior art keywords
functional group
branched alkyl
target protein
proteins
chromatography
Prior art date
Application number
AT04796067T
Other languages
English (en)
Inventor
Abhinav Shukla
Sanchayita Ghose
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE462716(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE462716T1 publication Critical patent/ATE462716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04796067T 2003-10-24 2004-10-22 Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen ATE462716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51448603P 2003-10-24 2003-10-24
PCT/US2004/035007 WO2005042569A1 (en) 2003-10-24 2004-10-22 Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction

Publications (1)

Publication Number Publication Date
ATE462716T1 true ATE462716T1 (de) 2010-04-15

Family

ID=34549339

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04796067T ATE462716T1 (de) 2003-10-24 2004-10-22 Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen

Country Status (8)

Country Link
US (1) US7427659B2 (de)
EP (1) EP1687328B1 (de)
AT (1) ATE462716T1 (de)
AU (1) AU2004285928B2 (de)
CA (1) CA2542951C (de)
DE (1) DE602004026343D1 (de)
ES (1) ES2342539T3 (de)
WO (1) WO2005042569A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380290A1 (de) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US7427659B2 (en) * 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
EP1869065B1 (de) 2005-03-11 2020-05-06 Wyeth LLC Verfahren zur chromatographie mit schwacher partition
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
AU2006267176A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
US7566401B2 (en) * 2005-10-03 2009-07-28 Kelm Mark A Process for separating and isolating xanthines, individual polar protic monomers, and polar protic oligomers
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
DK1969007T3 (da) * 2005-12-20 2013-11-25 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
BRPI0906429B1 (pt) 2008-01-10 2021-08-03 Research Development Foundation Método de identificação de uma infecção por e. chaffeensis em um indivíduo, uso de um ou mais polipeptídeo sintético e kit
WO2009126603A1 (en) * 2008-04-08 2009-10-15 Bio-Rad Laboratories, Inc. Chromatography purification of antibodies
EP2321336A1 (de) * 2008-07-18 2011-05-18 Talecris Biotherapeutics, Inc. Verfahren zur herstellung eines alpha-1-proteinaseinhibitors
KR20180000341A (ko) * 2009-06-16 2018-01-02 젠자임 코포레이션 재조합 ａａｖ 벡터에 대한 개선된 정제 방법
EP3366692A1 (de) 2009-06-22 2018-08-29 Amgen, Inc Proteinneufaltung mit einem chemisch gesteuerten redoxzustand
AU2010266093B2 (en) 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
WO2011053699A1 (en) 2009-10-30 2011-05-05 Abbott Laboratories Sorf constructs and multiple gene expression
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SG10201605397PA (en) 2011-07-01 2016-08-30 Hoffmann La Roche Method For Separation Of Monomeric Polypeptides From Aggregated Polypeptides
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
KR101454316B1 (ko) * 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
SG10201701224UA (en) 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
JP6592426B2 (ja) 2013-03-15 2019-10-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 無塩条件下で疎水性相互作用クロマトグラフィーを使用するタンパク質精製
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP6326499B2 (ja) 2013-12-12 2018-05-16 イー・エム・デイー・ミリポア・コーポレイシヨン アクリルアミド含有フィルターを使用したタンパク質分離
WO2015131978A1 (en) * 2014-03-04 2015-09-11 Merck Patent Gmbh Robust antibody purification
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
EP3668985B1 (de) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Verfahren zur reinigung von glykosyliertem protein aus wirtszellen-galectinen und anderen verunreinigungen
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
JP2023521384A (ja) 2020-04-09 2023-05-24 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗体を含む組成物
KR20230124578A (ko) 2020-12-22 2023-08-25 암젠 인크 세포 배양 방법
AU2023265659A1 (en) 2022-05-02 2024-12-12 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0449299A (ja) * 1990-06-14 1992-02-18 Tosoh Corp 免疫グロブリンフラグメントの精製法
US5463029A (en) * 1992-11-23 1995-10-31 Immunex Corporation Purification of fusion proteins comprising GM-CSF and IL-3
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5468847A (en) * 1994-03-10 1995-11-21 Minnesota Mining And Manufacturing Company Method of isolating and purifying a biomacromolecule
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
GB9907553D0 (en) * 1999-04-01 1999-05-26 Cantab Pharma Res Purification of biological preparations
AU4951501A (en) 2000-03-27 2001-10-08 Genetics Inst Methods for purifying highly anionic proteins
US7427659B2 (en) * 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction

Also Published As

Publication number Publication date
US7427659B2 (en) 2008-09-23
DE602004026343D1 (de) 2010-05-12
ES2342539T3 (es) 2010-07-08
AU2004285928B2 (en) 2012-02-02
AU2004285928A1 (en) 2005-05-12
EP1687328B1 (de) 2010-03-31
CA2542951C (en) 2016-08-30
US20050136521A1 (en) 2005-06-23
EP1687328A4 (de) 2006-11-15
EP1687328A1 (de) 2006-08-09
WO2005042569A1 (en) 2005-05-12
CA2542951A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE462716T1 (de) Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
HRP20180182T1 (hr) Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
TW200740839A (en) Methods of purifying Fc region containing proteins
ATE200293T1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
NZ587511A (en) Purified lymphotoxin-beta-receptor immunoglobulin fusion proteins and methods of their purification
ATE476505T1 (de) Verfahren zur isolierung von nukleinsäuren mit verwendung von ethylenglykol-multimeren
ATE425989T1 (de) Proteinreinigungsverfahren
EA201500952A1 (ru) Способы очистки рекомбинантного adamts13 и других белков и их композиции
DE68915675D1 (de) Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.
ATE525087T1 (de) Verfahren zur aufreinigung von antikörpern
EA200970231A1 (ru) СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ
RU2010103528A (ru) Очистка фактора viii с использованием смолы смешанного типа действия или мультимодальной смолы
ATE473244T1 (de) Festphase zur verwendung in einem verfahren zur reinigung von albuminkonjugaten
MX2024009755A (es) Metodos de purificacion de un producto.
ATE547521T1 (de) Verfahren zur reinigung von nukleinsäure
DE602004023626D1 (de) Trennung von polypeptiden mit einer racemisierten aminosäure
RU2010105312A (ru) Хроматографические способы
US12358946B2 (en) Method for purifying antibodies
DE69635661D1 (de) Methode zur reinigung von thrombopoietin
DE69926226D1 (de) Neues verfahren zur trennung von proteinen unter verwendung eines ca++ enthaltenden elutionsmittels
RU2018121657A (ru) ПРОТИВОПОЛОЖНЫЕ ГРАДИЕНТЫ pH-СОЛЬ ДЛЯ УЛУЧШЕННОГО РАЗДЕЛЕНИЯ БЕЛКОВ
DE69333141D1 (de) Verfahren zur reinigung einer rohen albuminwässerigen lösung
ATE496133T1 (de) Affinitätspolypeptid zur reinigung von rekombinanten proteinen
ATE426611T1 (de) Verfahren zur reinigung eines kalziumionen- bindenden proteins
DE602004008438D1 (de) Verfahren zur isolierung von hämocyanin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties